【禁忌】 strong>
•甲状腺髓样癌或2型多发性内分泌肿瘤综合征患者的个人或家族史(4)。
•已知对OZEMPIC®或任何产品成分过敏(4)。
p>
【 INDICATIONS AND USAGE 】
OZEMPIC® is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use:
•Not recommended as first-line therapy for patients inadequately controlled on diet and exercise (1, 5.1).
•Has not been studied in patients with a history of pancreatitis. Consider another antidiabetic therapy (1, 5.2).
•Not indicated for use in type 1 diabetes mellitus or treatment of diabetic ketoacidosis (1)
【DOSAGE AND ADMINISTRATION】
•Start at 0.25 mg once weekly. After 4 weeks, increase the dose to 0.5 mg once weekly. If after at least 4 weeks additional glycemic control is needed, increase to 1 mg once weekly (2.1).
•Administer once weekly at any time of day, with or without meals (2.1).
•If a dose is missed administer within 5 days of missed dose (2.1).
•Inject subcutaneously in the abdomen, thigh, or upper arm (2.2).
【DOSAGE FORMS AND STRENGTHS】
Injection: 2 mg/1.5 mL (1.34 mg/mL) available in:
•Single-patient-use pen that delivers 0.25 mg or 0.5 mg per injection (3).
•Single-patient-use pen that delivers 1 mg per injection (3).
【CONTRAINDICATIONS】
•Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (4).
•Known hypersensitivity to OZEMPIC® or any of the product components (4).
---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件(201911215205437.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------